Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Harbin Gloria, WuXi Biologics Sign $818 Million Deal for Ex-China Rights to PD-1 Candidate

publication date: Aug 17, 2017
Harbin Gloria Pharma and WuXi Biologics have entered an ex-China agreement for a PD-1 antibody with Arcus Biosciences of California's Bay Area in a deal worth up to $818 million. The PD-1 candidate, GLS-010, is currently in a China Phase I trial. Arcus will pay $18.5 million upfront for rights to GLS-010 in North America, Europe, Japan and other unspecified territories. It will also be liable for $422.5 million in development and regulatory milestones on combinations of GLS-010 and 11 Arcus products. Commercial milestones will add another $375 million to the agreement, and Arcus will also pay royalties on sales. More details....

Stock Symbols: (SHZ: 002437) (HK: 2269)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital